Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-10-05 / Front Immunol 2021;12:721830Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro
/in International Publications, Newcastle Disease Virus /von 2021-07-25 / Res Vet Sci 2021 Jul;139:159-165Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
/in International Publications, Newcastle Disease Virus /von 2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity
/in International Publications, Newcastle Disease Virus /von 2021-06-17 / Mol Cancer Ther 2021 Jun;A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
/in International Publications, Newcastle Disease Virus /von 2021-05-12 / Virol J 2021 May;18(1):98MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2021-04-21 / Oncol Lett 2021 Jun;21(6):482Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2021-03-30 / Int J Med Sci 2021;18(11):2294-2302The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-02-01 / Neurosurg Focus 2021 02;50(2):E8IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma